2020 Peptide Drug Design & Delivery Summit
The 2020 Peptide Drug Design & Delivery Summit will bring together key decision makers and innovators within this rapidly growing field. This intensive 3-Day program will examine various peptide discovery and synthesis techniques and synthesized and modified peptides. Hear from over 50 peptide drug commercialization experts on a variety of sessions including peptide engineering, peptidomimetics, peptide conjugation, and cell-penetrating peptides for molecular imaging.
Additionally, 2020’s Summit will examine novel strategies for improving peptide stability and half-life, along with novel routes of administration. Case studies will be presented that illustrate the progress made in developing efficacious peptide therapeutics, while leaders in the field point the way to the future for these promising drugs. Meet and network with 160+ drug development professionals and walk away wit over 2 years of new peptide commercialization strategies in just 3 days! Extra value: Attend this August and gain complimentary access to the popular 2020 Controlled & Modified Drug Release Summit (2 events co-located for the price of 1 registration).
You Will Learn
- Precision medicine & healthcare delivery: making precision medicine a reality via novel technology advancements
- Designing optimal peptides; Peptidomimetics Rational and structure-based design of novel peptides
- Peptide conjugation techniques
- Targeted & localized delivery
- Modeling & simulation approaches
- Cell penetrating peptides in molecular imaging and drug delivery
- Antimicrobial peptides in immunotherapy
- Peptide synthesis; Biosynthesis and modified peptides
- Discovery and development of protease inhibitors
Improve The Performance Of Your Peptide Drug Products
Meet 160+ peptide drug development professionals & learn over 2 YEARS worth of new product development strategies, formulation approaches, delivery technologies & regulatory updates while decreasing drug product time-to-market in just 3 days!
Stay Up To Date With The Latest Updates and Event Info
Beyond 2020, the global Peptide Therapeutics market is expected to eclipse $42 billion. This dramatic market increase is driven by both growing incidences of cardiovascular and metabolic diseases, and technological enhancements in peptide synthesis that include...
Controlled delivery formulations remain one of the favored tools for advancing the lifecycle of pharmaceutical products. A traditional strategy is to initially launch multiple daily doses of an immediate-release (IR) product, then reformulate into a once-daily...
There are a number of pharmacological and economical benefits to developing controlled and modified release drug products. Following the 505(b)(2) pathway allows companies to make modest changes to an already approved drug and get continued market exclusivity for a...
Thank You To Our Partners
2019 Speakers Included
Tycho Heimbach, PhD
Director, PK Sciences, PBPK and Biopharmaceutics, Novartis
Rakesh Dixit, PhD
Vice President, R&D, Head Biologics Safety Assessment, AstraZeneca
Mohammad Al-Sayah, PhD
Senior Scientist, Drug Product Development, Genentech Inc.
Eric Munson, PhD
Head, Department of Industrial and Physical Pharmacy, Purdue University
Yingkai Liang, PhD
Senior Scientist, Discovery Pharmaceutical Sciences, Merck & Co.
Jae Yoo, PhD
Chief Technology Officer, Aprecia Pharmaceuticals
Scott Shandler, PhD
Founder and CEO, Longevity Biotech
Vincent Ling, PhD
Senior Director, Advanced Technologies, Drug Product Development, Takeda
Di Bei, PhD
Senior Clinical Pharmacologist, Bristol-Myers Squibb
Victor Hruby, PhD
Regents Professor, Department of Chemistry, University of Arizona
Umar Maharoof, PhD
Associate Director, Dosage Form Development, Medimmune
Xiaoling Li, PhD
Associate Dean and Professor, University of the Pacific
John Lambris, PhD
Dr. Ralph and Sallie Weaver Professor of Research Medicine, University of Pennsylvania
Biplop Mitra, PhD
Principal Research Scientist, Drug Product Development, Celgene Corporation
Daniel Skomski, PhD
Senior Scientist, Merck
Shirlynn Chen, PhD
Distinguished Research Fellow, Boehringer Ingelheim